Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection

Supporting evidence

• Evaluation report

• Appraisal consultation committee papers (PDF 4.52 MB)

  Published:

  19 January 2022

• Final appraisal determination committee papers (PDF 1.52 MB)

  Published:

  19 January 2022